Core Points - The 11th batch of national organized drug procurement will take place on October 27, 2025, involving 55 drug varieties and over 400 participating companies [1] - The new procurement rules emphasize quality assurance and prevent price undercutting, with a new "anchor" price set at the higher of 50% of the average comparable price of valid applicants or the lowest comparable price [2] - There is intense competition for certain drug varieties, with nine varieties having more than 20 competing companies, indicating that over half will not qualify [3] Group 1 - The most competitive drug is theophylline injection, with 48 companies bidding, and a projected market size of 650 million yuan in 2024 [4] - Other highly competitive drugs include cefazolin injection with 41 bidders and famotidine injection with 38 bidders, with market sizes of approximately 2.6 billion yuan and 1.63 billion yuan respectively [4] - The procurement process introduces a "revival" opportunity for non-selected companies if they can accept the winning bid price [4] Group 2 - The National Medical Insurance Administration has set higher quality assurance requirements for bidding companies, mandating at least two years of production experience and compliance with GMP standards [5]
第十一批集采今日开标 超400家企业竞标 不再单纯追求最低价中标
Di Yi Cai Jing·2025-10-27 00:56